UK Markets closed

CompuGroup Medical SE & Co. KGaA (0MSD.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
66.20+2.20 (+3.44%)
At close: 5:50PM BST
Full screen
Previous close64.00
Open64.00
Bid0.00 x N/A
Ask0.00 x N/A
Day's range64.00 - 66.55
52-week range64.00 - 66.55
Volume1,427
Avg. volumeN/A
Market cap3.204B
Beta (5Y monthly)0.80
PE ratio (TTM)47.29
EPS (TTM)1.40
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    CompuGroup Medical benefits from digitization in healthcare with dynamic growth in the first quarter

    DGAP-News: CompuGroup Medical SE & Co. KGaA / Key word(s): Quarter Results06.05.2021 / 07:24 The issuer is solely responsible for the content of this announcement. Strong growth of group revenues with +25 %, organic growth accelerates to +5 % Adjusted EBITDA increased by 7 % with simultaneous launch of investment program CGM supports customers in their courageous fight against COVID-19 with numerous initiatives Hospital Information Systems (HIS) business in excellent shape Successful continued rollout of Telematics Infrastructure to pharmacies Dynamic growth in data-based business Recurring revenues now 69 % of total revenues Strong free cashflow despite increased investments for further growthKoblenz. CompuGroup Medical SE & Co. KGaA (CGM) is reporting a strong start to the year 2021. Especially against the background of the COVID-19 pandemic, the Koblenz-based company - one of the leading e-health providers in the world - is fully on track based on the first quarter results published today. The demand for solutions that help healthcare providers, governments and citizens cope with the ongoing pandemic remains high, especially since most countries have started providing vaccinations to their citizens. The provision of a vaccination module for doctors' software in Germany, the support of electronic documentation of vaccinations in Austria and a platform for online appointments in Italy are only some of the solutions that CGM is providing in this area.CGM also announced a cooperation with Universitätsklinikum Hamburg-Eppendorf (UKE), one of Europe's leading university clinics and a pioneer in the digitization of healthcare, who will take a step forward by using the Hospital Information System (HIS) CGM CLINICAL. In addition, there was a promising start with regard to the Hospital Future Act with intense discussions with customers and a high number of leads."For the first quarter, we are completely on track, while we are investing into research and development, sales and distribution capabilities to enable further growth. Digitization is becoming an indispensable part of healthcare and CGM is a crucial contributor to this," said Dr. Dirk Wössner, CEO of CompuGroup Medical, and added, "Our deep gratitude goes to the frontline fighters in this pandemic. We are passionately supporting our customers: doctors, nurses and all healthcare professionals in their courageous fight against COVID-19, for example supporting the vaccination process."Michael Rauch, CFO of CompuGroup Medical, added, "The first quarter showed dynamic growth with margins below the prior year in line with our planned growth investments. We are very happy with our free cashflow development which has been significantly better than prior year and also benefitted from one-time effects."Dynamic growth in the first quarterOverall, CGM recorded a strong first quarter with group revenues increasing by 25 % to EUR 229 million (previous year: EUR 183 million). Organically - i.e. adjusted for consolidation and currency effects - it rose by 5 %. Recurring revenues account for 69 % of total revenue compared to previous year's 67 % within the Group. Adjusted EBITDA increased by 7 % from EUR 43 million in the first quarter of 2020 to EUR 47 million.Below the line, CGM generated a consolidated profit of EUR 11 million in the first quarter (previous year: EUR 13 million). Adjusted earnings per share (diluted) amounted to EUR 0.33 (previous year: EUR 0.34), while free cashflow reached EUR 70 million (previous year: EUR 51 million).CGM confirms its guidance for the full year. For 2021, revenues in the range of EUR 1 billion to EUR 1.04 billion are expected. The adjusted EBITDA for 2021 is expected to be between EUR 210 million and EUR 230 million.Segments: Recurring revenue growth across all segmentsThe Ambulatory Information Systems (AIS) segment increased revenues by 18 % to EUR 112 million (previous year: EUR 95 million). The share of recurring revenues increased from 73 % in the prior-year quarter to 77 %. Due to a strong business with the rollout of Windows 10 in the first quarter of 2020, revenues were organically slightly below the prior year's level. The segment generated an adjusted EBITDA of EUR 30 million (previous year: EUR 27 million). Operating margin was 26 %, compared to the 29 % in the same quarter of the previous year, impacted by increased investments into R&D, sales, and distribution and by the lower margin of the newly consolidated US business.The Hospital Information Systems (HIS) segment showed strong revenue growth of 64 % to EUR 55 million (previous year: EUR 34 million) due to the acquisition of parts of the Cerner portfolio in 2020. The organic revenue growth of 8 % is based on a very good business development in Germany. The adjusted EBITDA amounted to EUR 7.6 million (previous year: EUR 4.2 million) with an operating margin of 14 % slightly above the previous year (13 %) despite additional investments.The Consumer & Health Management Information Systems (CHS) segment increased revenues significantly by 33 % to EUR 34 million (previous year: EUR 25 million), among other things driven by the ongoing rollout of the Telematics Infrastructure (TI) to pharmacies. Excluding TI, the organic revenue increase was +9 %, mostly driven by a strong growth of the German data business. The adjusted EBITDA amounted to EUR 5.2 million and 6 % above the previous year's figure (EUR 4.9 million). The margin was down due to a higher share of TI hardware revenues and growth investments.The Pharmacy Information Systems (PCS) segment posted revenues of EUR 28 million, slightly below the previous year (EUR 29 million) which had benefitted still from the Windows 10 rollout. Adjusted EBITDA decreased by EUR 0,9 million to EUR 8.0 million (previous year: EUR 8.9 million), due to higher investments. The full quarterly report is available on the company's website at www.cgm.com/ir-publications. About CompuGroup Medical SE & Co. KGaACompuGroup Medical is one of the leading e-health companies in the world. With a revenue base of EUR 837 million in 2020, its software products are designed to support all medical and organizational activities in doctors' offices, pharmacies, laboratories and hospitals. Its information services for all parties involved in the healthcare system and its web-based personal health records contribute towards safer and more efficient healthcare. CompuGroup Medical's services are based on a unique customer base of more than 1.6 million users, including doctors, dentists, pharmacists and other health professionals in inpatient and outpatient facilities. With locations in 18 countries and products in 56 countries worldwide, CompuGroup Medical is the eHealth company with one of the highest coverages among e-health service providers. Approximately 8,000 highly qualified employees support customers with innovative solutions for the steadily growing demands of the healthcare system.Contact for media representatives:Michael FranzHead of Brand CommunicationP +49 (0) 261 8000-6100F +49 (0) 261 8000-3100E-mail: press@cgm.comContact for analysts and investors:Claudia ThoméCorporate Vice President Investor RelationsP +49 (0) 261 8000-7030F +49 (0) 261 8000-3200E-mail: claudia.thome@cgm.com06.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: CompuGroup Medical SE & Co. KGaA Maria Trost 21 56070 Koblenz Germany Phone: +49 (0)261 8000 7030 Fax: +49 (0)261 8000 3200 E-mail: investor@cgm.com Internet: www.cgm.com ISIN: DE000A288904 WKN: A28890 Indices: MDAX, TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1193125 End of News DGAP News Service

  • EQS Group

    Universitätsklinik Hamburg-Eppendorf (UKE) decides for a future with CGM CLINICAL

    DGAP-News: CompuGroup Medical SE & Co. KGaA / Key word(s): Miscellaneous15.04.2021 / 09:05 The issuer is solely responsible for the content of this announcement.Koblenz. CompuGroup Medical (CGM), one of the world's leading providers of e-health solutions, announced today that the medical center Universitätsklinik Hamburg-Eppendorf (UKE), one of Europe's leading university clinics, selected the CGM CLINICAL hospital information system as the core enterprise-wide electronic health record (EHR) system. For more than a decade, UKE has been a pioneer in digitization of healthcare and is now taking the next step by choosing an innovative partner. Using cutting-edge features will further propel UKE's experience in case as part of an integrated patient journey. UKE is one of Europe's highly reputable clinics with more than 13,500 employees. It is characterized by state-of-the-art medical technology, innovative information technology (UKE has been certified as Europe's first fully digital hospital), and architecture created with the goal of medical excellence, all patient-centric and with set up to optimally supporting doctors, nursing staff, and therapists. At the UKE clinic, healthcare and research go hand in hand, which is impressively shown by the research results achieved in the recent months - in parallel to patient care - on the Corona Virus.CGM prevailed among many other competitors in a two-year award process and was awarded the contract. UKE will use the entire spectrum of CGM CLINICAL medical modules, based on the CGM CLNICAL data model CDM+ which is highly structured, yet open and flexible. This will enable numerous new ways of using data for both research and excellent care."At UKE, we are dedicated to delivering care with an understanding of the whole patient journey," said Professor Christian Gerloff, Vice Medical Director of UKE, "We are convinced that CGM is the perfect partner for a healthcare organization like us, and that CGM CLINICAL can enable all our healthcare professionals to deliver excellent and integrated care based on cutting-edge technology."Marco Siebener, CIO of UKE, added, "Coming from a very high standard of digitization already, we now want to achieve the next level. Therefore, we must tackle challenges in fields of personalized medicine, smart data, real-time analytics and clinical decision support, as well as effective connectivity across sectors with patients and colleagues. Together with CGM, we see the potential for game-changing approaches.""The largest order for our cutting-edge G3 platform in Germany - and the second largest in this segment - from one of the best university clinics in Europe confirms our strategy. Our investments into G3 are thus paying off," emphasized Dr. Dirk Wössner, CEO of CompuGroup Medical, "We are proud to support one of the European leaders in medical excellence and digitization in healthcare with our innovative CGM CLINICAL solutions."Hannes Reichl, Managing Director Inpatient and Social Care at CGM, added, "UKE's decision marks another major milestone in the rollout of CGM CLINICAL and once more proofs its innovative strength. This state-of-the-art product will enable UKE to enhance its processes, which are already digitized along the entire patient journey, even more flexibly and precisely fitting the requirements of a dynamic university clinic. CDM+ data model will thus strengthen communication and connectivity within UKE's facilities, but also with healthcare providers in other clinical or ambulatory institutions."The partners agreed to start the project in May 2021, with a duration of 4 years. There will be a step-by-step rollout across UKE, with the common goal of a first rollout in 2022. The implementation will start in the UKE's Martini Clinic, a highly specialized prostate Cancer Center, and the University Heart & Vascular Center, both in entirely new buildings.About UKESince its foundation in 1889, the Medical Center Hamburg-Eppendorf (UKE) has been one of the leading clinics in Europe. With about 13,600 employees, the UKE is one of the largest employer in the Free and Hanseatic City of Hamburg. The UKE treats about 511,000 patients a year, 106,000 of whom are inpatients and 405,000 are outpatients. The emphasis in UKE's research are the neurosciences, cardio-vascular research, care research, oncology, as well as infections and inflammations. Other potential areas of the UKE are molecular imaging and skeletal biology research. The UKE educates about 3,400 medical specialists and dentists.Knowledge, Research, Healing through Shared Competence: The UKE | www.uke.de About CompuGroup Medical SE & Co. KGaACompuGroup Medical is one of the leading e-health companies in the world. With a revenue base of EUR 837 million in 2020, its software products are designed to support all medical and organizational activities in doctors' offices, pharmacies, laboratories and hospitals. Its information services for all parties involved in the healthcare system and its web-based personal health records contribute towards safer and more efficient healthcare. CompuGroup Medical's services are based on a unique customer base of more than 1.6 million users, including doctors, dentists, pharmacists and other health professionals in inpatient and outpatient facilities. With locations in 18 countries and products in 56 countries worldwide, CompuGroup Medical is the eHealth company with one of the highest coverages among eHealth service providers. Approximately 8,000 highly qualified employees support customers with innovative solutions for the steadily growing demands of the healthcare system.Contact for media representatives:Michael FranzHead of Brand CommunicationP +49 (0) 261 8000-6100F +49 (0) 261 8000-3100E-mail: press@cgm.comContact for analysts and investors:Claudia ThoméCorporate Vice President Investor RelationsP +49 (0) 261 8000-7030F +49 (0) 261 8000-3200E-mail: claudia.thome@cgm.com15.04.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: CompuGroup Medical SE & Co. KGaA Maria Trost 21 56070 Koblenz Germany Phone: +49 (0)261 8000 7030 Fax: +49 (0)261 8000 3200 E-mail: investor@cgm.com Internet: www.cgm.com ISIN: DE000A288904 WKN: A28890 Indices: MDAX, TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1184966 End of News DGAP News Service

  • EQS Group

    CompuGroup Medical SE & Co. KGaA adopts resolution on share buy-back program for up to 500,000 treasury shares

    CompuGroup Medical SE & Co. KGaA / Key word(s): Share BuybackCompuGroup Medical SE & Co. KGaA adopts resolution on share buy-back program for up to 500,000 treasury shares25-Feb-2021 / 20:00 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement. The general partner of CompuGroup Medical SE & Co. KGaA (the "Company") (ISIN: DE000A288904 | WKN: A28890), utilising the authorization granted by its annual general meeting of May 15, 2019 and pursuant to section 71(1) no. 8 of the German Stock Corporation Act (Aktiengesetz), resolved today to buy back a maximum number of up to 500,000 shares of the Company (corresponding to approx. 0.93% of the Company's share capital) at a maximum purchase price (excluding transaction costs) of up to EUR 40,000,000.00 in total (the "Share Buy-back Program").The Share Buy-back Program will be carried out by a credit institution. The credit institution will acquire the shares on the stock market and will decide on the timing of acquisition independently of the Company in accordance with the safe harbor provisions of Article 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 (Market Abuse Regulation) in conjunction with the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016. In addition, the purchase price per share (excluding transaction costs) paid must not exceed, or fall short of, the volume-weighted average price of the Company's share in XETRA trading on the Frankfurt Stock Exchange during the last five trading days before the acquisition date by more than 10%.Shares will be bought back in the period from February 26, 2021 to and including April 30, 2021. The Company's treasury shares acquired by means of the Share Buy-back Program are to be used for the purposes permitted under the authorization granted by the annual general meeting of May 15, 2019.Further details will be published separately by the Company prior to the start of the share buy-back.25-Feb-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: CompuGroup Medical SE & Co. KGaA Maria Trost 21 56070 Koblenz Germany Phone: +49 (0)261 8000 7030 Fax: +49 (0)261 8000 3200 E-mail: investor@cgm.com Internet: www.cgm.com ISIN: DE000A288904 WKN: A28890 Indices: MDAX, TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1171325 End of Announcement DGAP News Service